For adjuvant endocrine therapy in premenopausal breast cancer patients, patients may choose to undergo either excisional debulking or functional suppression of the ovaries with or without TAM for 2-3 years as a basic option. (1) If patients enter menopause, they may choose to continue to complete 5 years of TAM therapy on the one hand and receive 5 years of trimethoprim therapy thereafter; on the other hand, they may also consider switching to exemestane or anastrozole to complete 5 years of adjuvant endocrine therapy. (2) If the patient is still in premenopausal status, he/she should complete 5 years of TAM treatment. after 5 years of TAM adjuvant endocrine therapy, if the patient enters menopause, he/she can receive another 5 years of trimethoprim therapy; if he/she is still in premenopause, he/she does not need to continue endocrine therapy. For postmenopausal breast cancer patients, (1) 5 years of anastrozole or letrozole can be one of the options; (2) 2-3 years of TAM treatment, during which time the patient switches to exemestane or anastrozole to complete 5 years of endocrine therapy; (3) 4.5-6 years of TAM followed by 5 years of letrozole; (4) when the patient is accompanied by contraindications to AIs, or the patient subjectively refuses to receive AIs, or the patient cannot tolerate the toxic effects of AIs, TAM for 5 years should be the standard choice.